Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zastumotide - GlaxoSmithKline

Drug Profile

Zastumotide - GlaxoSmithKline

Alternative Names: Astuprotimut-R; D1/3 MAGE-3 fusion protein; D1/3 MAGE-3 fusion protein SB MAGE-3; D1/3 MAGE-3 His; D1/3 MAGE-3 His fusion protein; GSK 1572932A; GSK 2132231A; GSK 249553; GSK1203486A; MAGE-A3; MAGE-A3 antigen specific cancer immunotherapeutic; MAGE-A3 ASCI; NSC 719274; SB 249553; SB MAGE-3; SID 534984

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; Ludwig Institute for Cancer Research
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines; Recombinant fusion proteins
  • Mechanism of Action Immunostimulants; MAGEA 3 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Bladder cancer; Malignant melanoma; Multiple myeloma; Non-small cell lung cancer

Most Recent Events

  • 14 Apr 2021 Discontinued - Phase-II for Malignant melanoma (Combination therapy, Inoperable/Unresectable) in USA (IM) (GSK website, April 2021)
  • 14 Apr 2021 Discontinued - Phase-II for Malignant melanoma (Combination therapy, Metastatic disease) in France, Belgium (IM) (GSK website, April 2021)
  • 14 Apr 2021 Discontinued - Phase-II for Malignant melanoma (Inoperable/Unresectable) in Russia, Belgium, France, USA, Finland, Germany, Spain, Poland, Italy, Ireland (IM) (GSK website, April 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top